Steris Corp. (STE) Earns Neutral Rating from Analysts at Goldman Sachs Group Inc.
Goldman Sachs Group Inc. began coverage on shares of Steris Corp. (NYSE:STE) in a research report issued to clients and investors on Wednesday. The firm set a “neutral” rating on the stock.
Several other equities analysts have also issued reports on the company. Zacks Investment Research raised Steris Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, November 22nd. JMP Securities reissued a “buy” rating on shares of Steris Corp. in a research note on Friday, November 4th.
Shares of Steris Corp. (NYSE:STE) opened at 66.89 on Wednesday. The stock has a 50 day moving average price of $67.37 and a 200 day moving average price of $69.42. The firm has a market cap of $5.70 billion, a P/E ratio of 33.77 and a beta of 1.30. Steris Corp. has a 12-month low of $61.38 and a 12-month high of $78.77.
Steris Corp. (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by $0.01. Steris Corp. had a net margin of 6.41% and a return on equity of 9.89%. The business earned $646.40 million during the quarter, compared to analyst estimates of $670.24 million. During the same period last year, the firm posted $0.83 earnings per share. Steris Corp.’s quarterly revenue was up 31.9% compared to the same quarter last year. On average, equities analysts expect that Steris Corp. will post $3.90 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 21st. Stockholders of record on Wednesday, November 23rd will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $1.12 annualized dividend and a dividend yield of 1.67%. Steris Corp.’s dividend payout ratio is 57.14%.
In related news, Director Richard Martin Steeves sold 204,778 shares of the company’s stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $71.19, for a total transaction of $14,578,145.82. Following the completion of the sale, the director now owns 165,434 shares in the company, valued at $11,777,246.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cynthia L. Feldmann sold 4,744 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $64.98, for a total value of $308,265.12. Following the sale, the director now owns 14,581 shares of the company’s stock, valued at approximately $947,473.38. The disclosure for this sale can be found here. Insiders own 2.52% of the company’s stock.
Large investors have recently made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Steris Corp. by 8.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,398 shares of the company’s stock valued at $102,000 after buying an additional 112 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in shares of Steris Corp. by 26.3% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 1,528 shares of the company’s stock valued at $112,000 after buying an additional 318 shares during the period. Amica Retiree Medical Trust bought a new stake in shares of Steris Corp. during the third quarter valued at about $119,000. D.A. Davidson & CO. increased its stake in shares of Steris Corp. by 19.8% in the third quarter. D.A. Davidson & CO. now owns 1,812 shares of the company’s stock valued at $131,000 after buying an additional 300 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of Steris Corp. by 85.8% in the second quarter. Bessemer Group Inc. now owns 1,942 shares of the company’s stock valued at $134,000 after buying an additional 897 shares during the period. Institutional investors and hedge funds own 91.99% of the company’s stock.
About Steris Corp.
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Receive News & Stock Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related stocks with our FREE daily email newsletter.